ReviewCardiovascular endocrinology & metabolism2026
Effectiveness of plasma atherogenic index as a predictor of cardiovascular risk in patients with metabolic syndrome and related cardiometabolic conditions: a systematic review.
Review in Cardiovascular endocrinology & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) and cardiovascular-kidney-metabolic syndrome represent escalating global health challenges characterized by complex lipid derangements. While traditional lipid panels are standard, the atherogenic index of plasma (AIP) has emerged as a potentially superior marker for capturing the presence of small, dense low-density lipoprotein particles and overall cardiovascular risk. This systematic review evaluates the prognostic value and longitudinal risk prediction of AIP in patients with MetS and related metabolic disorders. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic search was conducted across PubMed/MEDLINE, Scopus, Embase, and Web of Science through January 2026. Nine high-quality studies encompassing 197 279 patients were identified. Synthesis of the evidence consistently demonstrates that elevated baseline AIP is consistently and independently associated with major adverse cardiovascular events (hazard ratio: 1.07-1.19), acute myocardial infarction, and cardiovascular death. Longitudinal data reveal that cumulative AIP exposure significantly increases stroke risk (hazard ratio: 2.49) and coronary heart disease. Notably, in patients with diabetic kidney disease, a nonlinear 'U-shaped' association was identified, with a critical inflection point at 0.14, suggesting that both excessively high and low AIP levels correlate with increased mortality. AIP is an accessible and promising biomarker that warrants further comparative validation in predicting long-term cardiometabolic progression. These findings support further evaluation of AIP's role in clinical risk stratification, pending prospective validation and establishment of standardized thresholds across population subgroups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.